Prot #HCRN LUN18-335/NU MDA20L01: An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-naïve EGFR-mutant Locally Advanced or Metastatic NSCLC

Project: Research project

Project Details

StatusActive
Effective start/end date1/14/21 → 1/14/24

Funding

  • Hoosier Cancer Research Network, Inc. (Prot #HCRN LUN18-335/NU MDA20L01)
  • Lilly USA, LLC (Prot #HCRN LUN18-335/NU MDA20L01)